19/02/2026
The New HIV Prevention Drug
Lenacapavir, a groundbreaking long-acting injectable drug for HIV prevention, has officially arrived in Kenya with an initial delivery of 21,000 doses. Developed over two decades, the drug's journey began with biochemical research into the HIV virus's capsid protein, which protects its genetic material. Scientists discovered that disrupting this protein's structure effectively neutralized the virus's ability to infect cells. Following years of refinement and clinical trials that began in 2018, the drug was named the 2024 "Breakthrough of the Year" by Science magazine for its unprecedented efficacy.
The clinical success of Lenacapavir is historic, with the PURPOSE 1 study involving 8,000 women in South Africa and Uganda reporting a 100 percent efficacy rate. Further trials confirmed its high performance, leading to approval by the U.S. FDA in June 2025 and subsequent endorsement by the World Health Organization (WHO). Unlike previous prevention methods that required daily pills or injections every two months, Lenacapavir is administered only twice a year. This six-month interval makes it the longest-acting HIV prevention option currently available, offering a discreet and highly effective choice for those at risk.
Safety assessments indicate that the drug is generally well-tolerated, with the most common side effect being mild, temporary reactions at the injection site. Extensive studies have shown no significant adverse impacts on pregnant or breastfeeding individuals, nor does the drug interfere with hormonal contraception or gender-affirming therapies. In early 2026, Kenya’s Pharmacy and Poisons Board officially registered both the injectable and tablet forms of the drug, clearing the way for its integration into the national healthcare system alongside existing PrEP options like Truvada and the dapivirine vaginal ring.
The rollout in Kenya is being managed through a phased approach, with 15 priority counties selected for the initial distribution based on high HIV prevalence and burden. These counties are Siaya, Homa Bay, Migori, Kisumu, Kisii, Mombasa, Nairobi, Machakos, Kajiado, Busia, Kiambu, Kilifi, Kakamega, Uasin Gishu, and Nakuru. Funded by the Global Fund in partnership with the Kenyan government, the drug will be provided free of charge at public health facilities. To maintain the twice-yearly schedule for early adopters, a second shipment of 12,000 doses is expected by April 2026, with plans to expand to a second phase of 15 additional counties before eventually covering all 47 counties nationwide.
